PubMed Health⌕ Search

Biomedical subjects

G Harrer

Publications and source records attributed to G Harrer.

At least 19 recordsLinked to original sources

Degree of hypomyelination and magnetic resonance spectroscopy findings in patients with Pelizaeus Merzbacher phenotype.

As only 10 - 30 % of patients with a Pelizaeus Merzbacher disease (PMD) phenotype carry mutations of the proteolipid protein (PLP) gene, we were interested if the degree and time-dependent progression of abnormal MRI and MRS findings would discriminate patients with mutations of the PLP gene (Pelizaeus Merzbacher disease, PMD) from patients without a defect of the PLP gene (Pelizaeus Merzbacher-like disease, PMLD). For a standardised intraindividual follow-up and for comparison of the degree of hypomyelination, we have applied a newly developed semiquantitative myelination score on a total of 18 MRI series of 4 PMD and 4 PMLD patients. We found severe hypomyelination (< 50 % of normal) in 2 PMD and in 2 PMLD patients, moderate hypomyelination (< 75 % of normal) in 2 PMD and mild hypomyelination (> 75 % of normal) in 2 PMLD patients. Our score revealed a clear correlation between the degree of hypomyelination and the severity of clinical handicap in PMD but not in PMLD patients. MRS showed heterogeneous cerebral metabolite patterns in both patient groups and seems to reflect a mixture of unspecific changes due to primary hypomyelination and secondary gliosis and demyelination. Neither by MRI nor by MRS were patterns found that would allow differentiation between PMD and PMLD patients.

Adolescent↗

[Hypericum and phototherapy].

A sunlight deficiency, as is experienced at our latitude in winter, induces a seasonal affective disorder (SAD) or winter depression in some people. First line of treatment of this form of depression is bright-light therapy, as a type of substitution therapy. SAD is treated with similar success using antidepressant drugs like hypericum (St. John's wort). Phototherapy also has an antidepressive effect on non-seasonal depressions, albeit not quite as pronounced. When using phototherapy light is transformed into electric impulses in the retina. These impulses are transmitted to the hypothalamus and the central nervous structures controlling metabolism, hormones and the circadian rhythms. These processes are governed by very complex regulatory mechanisms. Feedback loop mechanisms induce constant adaptation of the photosensitivity of the retinal photoreceptors while also controlling the central nervous structures. New findings on the interaction and interweaving of depression, light, metabolism, hormones and circadian rhythms support the following hypothesis: The photodynamic impact of hypericum magnifies the effect of normal light, as if the patient were subject to continuous light therapy. The photosensitizing effect of hypericum is thus not only of interest as an undesirable side-effect but also for its therapeutic effects.

Combined Modality Therapy↗

Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine.

In a randomised double-blind comparative trial, the antidepressant efficacy of a daily dose of 800 mg of the St. John's wort extract LoHyp-57 (dry extract of St. John's wort, drug extrakt ratio 5-7:1, solvent, ethanol 60% [w/w]) was shown to be equivalent to that of 20 mg fluoxetine (CAS 54910-89-3) in elderly patients with mild or moderate depressive episodes according to ICD 10 (International Statistical Classification of Diseases and Related Health Problems). Treatment was given for six weeks. 149 out-patients (129 females and 20 males) were included in the intention-to-treat analysis. 72 of these patients were assigned to the ICD 10 diagnostic criterion F32.0 (mild depressive episode), while 77 patients were suffering from moderate depressive episodes, corresponding to F32.1. The principal target criterion was the patient's global score on the HAMILTON Depression Scale (items 1-17). During the six-week course of treatment with LoHyp-57, the HAMILTON global score fell from 16.60 points at entry to 7.91 points, and in the fluoxetine sample it fell from 17.18 to 8.11 points. In the group of patients with mild depressive episodes, the score showed a mean fall from 14.21 to 6.21 points on LoHyp-57, and from 15.21 to 7.46 points on fluoxetine. In patients with moderate depressive episodes, the score showed a mean fall from 18.73 to 9.43 points on LoHyp-57 and from 19.10 to 8.75 points on fluoxetine. The efficacy of both medications was found to be equivalent both in mild and moderate depressive episodes. Both treatment groups showed adverse drug reactions (ADRs). Twelve ADRs with a possible relationship to the study medication were reported during treatment with LoHyp-57. Six patients were prematurely withdrawn from treatment with the study medication for this reason. On fluoxetine 17 ADRs occurred with a possible relationship to the study medication. These led to abandonment of treatment and therefore premature withdrawal from the study in 8 cases.

Aged↗

High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer.

The purpose of this study was to evaluate the efficacy of high-dose chemotherapy (HDC) with busulfan, melphalan and thiotepa (BUMELTT) followed by autologous PBSC infusion in treating patients with advanced ovarian cancer. Thirty-one patients, 18 with stage III/IIIc and 13 with stage IV ovarian cancer, were treated with BU (12 mg/kg), MEL (100 mg/m2) and TT (500 mg/m2) and autologous PBSC rescue. Fifteen patients were in clinical complete remission (CR) at treatment; 11 had platinum-sensitive disease. Sixteen patients were not in CR; two had platinum-sensitive disease. The probabilities of overall survival (OS), event-free survival (EFS) and relapse (R) for all patients at 18 months were 0.57, 0.30 and 0.63; for patients in CR, the rates were 0.87, 0.44 and 0.49 and for patients not in CR, 0.38, 0.13 and 0.81. Two patients (6.5%) died of treatment-related causes. Among the 13 patients with platinum-sensitive disease, all are still alive, with seven having relapsed 129-1021 days after PBSC infusion. OS, EFS and R were 1.00, 0.52 and 0.48. Of the 18 patients with platinum-resistant disease, four remain alive (two in remission). Six patients did not respond and eight relapsed from days 104-429. The OS, EFS and R were 0.33, 0.11 and 0.78. We conclude that BUMELTT is well tolerated in patients with advanced ovarian cancer and results are equivalent to other published HDC regimens.

Adult↗

[Treatment of depressive symptoms with a high concentration hypericum preparation. A multicenter placebo-controlled double-blind study].

In a multicenter, placebo-controlled double-blind trial, the effect on depression (ICD 10 F 32.1) of treatment with an innovative highly concentrated hypericum preparation was investigated. The study contained 97 outpatients who received 100 to 120 mg of the hypericum extract bid. The course of the illness was assessed with the Hamilton Depression Scale (HAMD), the von Zerssen Depressivity Scale (D-S) and the Clinical Global Impression Scale (CGIS). Treatment resulted in an appreciable improvement in the symptoms of depression, and the 70% response rate (n = 43), corresponded to that of chemical antidepressants. The preparation also showed an anxiolytic effect. The substance was extremely well tolerated, and no side-effects were reported by any of the patients.

Administration, Oral↗

[Not Available].

Explore the source record for details and available documents.

History, 15th Century↗

[Not Available].

Explore the source record for details and available documents.

Europe↗

Clinical investigation of the antidepressant effectiveness of hypericum.

To date, 25 controlled therapy studies have investigated the antidepressive effectiveness of hypericum extracts. A total of 1592 treatment cases have been included. The dosage was typically 300 to 900 mg total extract daily; the therapy duration was 2 to 6 weeks. Fifteen studies were performed comparing hypericum extracts with placebo, 10 studies as comparative studies. This paper presents an overview of their results.

Antidepressive Agents↗

Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients.

One hundred and five outpatients with mild depressions of short duration were treated in a double-blind study with either 3 x 300 mg hypericum extract or placebo. The therapy phase was 4 weeks. The effectiveness was judged according to the Hamilton Depression Scale after 2 and 4 weeks. The values of the mean basic score in these periods fell from 15.8 to 9.6 or 7.2 in the active group, and in the placebo group, from 15.8 to 12.3 and 11.3. The differences between active and placebo groups were statistically significant with P < .05 and P < .01 achieved after 2 and 4 weeks, respectively. In the active group, 28 of 42 patients (67%) and, in the placebo group, 13 of 47 patients (28%) responded to treatment. Notable side effects were not found.

Adult↗

Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study.

A randomized, double-blind study examining the effectiveness and tolerance of a standardized hypericum preparation when compared to maprotiline was performed in a group of 102 patients with depression, in accordance with ICD-10, F 32.1. The study was conducted in the offices of neurology and psychiatry specialists. The patients received, over a period of 4 weeks, either 3 x 300 mg of the hypericum extract or 3 x 25 mg maprotiline pills of identical appearance. Effectiveness was determined using the Hamilton Depression Scale (HAMD), the Depression Scale according to von Zerssen (D-S), and the Clinical Global Impression Scale (CGI). The total score of the HAMD scale dropped during the 4 weeks of therapy in both treatment groups by about 50%. The mean values of the D-S scale and the CGI scale showed similar results, and after 4 weeks of therapy, no significant differences in either treatment group were noticed. The onset of the effects occurred up to the second week of treatment, but were observed earlier with maprotiline than with the hypericum extract. On the other hand, maprotiline treatment resulted in more cases of tiredness, mouth dryness, and heart complaints.

Adult↗

[The usefulness of event-related negativity in demonstrating the therapeutic effects of nootropic drugs using cerebrolysin as an example].

This study investigated the usefulness of the Contingent Negative Variation (CNV) in the assessment of therapeutic efficacy of a nootropic substance, Cerebrolysin. A total of 41 geriatric patients with the diagnosis of moderate organic brain syndrome of different etiology were included in this randomized placebo-controlled double-blind study. After ten Cerebrolysin- plus multi-vitamins-Infusions, the treatment group of 27 patients showed a significant CNV-amplitude increase as compared to pre-treatment values. In the placebo group of 14 patients CNV-amplitudes even decreased after ten Infusions with multi-vitamins alone. These findings were interpreted in line with the vigilance model of nootropic drug effects as a vigilance-increasing effect of Cerebrolysin, i.e. as an increased neuronal performance readiness. The results confirmed the usefulness of the CNV method by providing an EEG-index of nootropic drug effects.

Aged↗

Contingent negative variation (CNV) differences between cerebrovascular patients with and without dementia.

This study investigated the clinical usefulness of the contingent negative variation (CNV) as a neurophysiological index of cognitive dysfunction associated with cerebrovascular disease. A total of 31 patients ranging in age from 45 to 88 years with the diagnosis of a stroke were included. Nineteen patients were classified as demented according to clinical assessment and the Mental Deterioration Index (MDI) based on the WAIS, the other 12 patients as non-demented. In a discriminative CNV-paradigm two different tones served as warning stimuli for a flash of light presented 1.5 s later that could be turned off by a press on a button only after the relevant tone. According to our hypothesis, CNV amplitudes of demented patients were significantly smaller than those of the non-demented group. Moreover, a significant relationship was observed between severity of dementia (MDI) and degree of amplitude reduction. Thus, it was concluded that the CNV method could make an important clinical contribution to the assessment and course of dementia.

Aged↗

Depression and criminality.

The delinquency of the depressed numerically only plays an unimportant role. The 'extended suicide' is regarded as the most typical and simultaneously most tragic delict. Almost exclusively this concerns severely depressed young mothers of 30 to 40 years of age, who in a delusional frame of mind include their children in their suicide, in order to prevent them from a presumably unavoidable disaster. Suicidality and aggressivity are intimately related phenomena, which should be treated in a forensic-psychiatric manner. Criminal acts, such as sexual and property delicts arising from an acting out of inner tension, may occur in anxiety or manic-depressive states of a mixed character. Although as a whole infrequent, the criminogenous importance of especially milder forms of depression is obviously often overlooked.

Aged↗

[Disorders of the neurotransmitter system in multiple sclerosis--possibilities for a therapeutic approach?].

The type and extent of neurological deficits in multiple sclerosis depends on the localisation and size of the lesion and the type of neuropathological pattern of the lesion. The elective demyelinating process (loss of myeline sheath without axonal damage) brings, about a showing and faulty conduction of impulses and thereby a disturbed processing of information. It can finally come to a total (functional, reversible) conduction blockage. Additionally also disturbances in the synaptic transmission may be involved. The occurrence and extent of these disturbances in conduction and transmission depend on definite paristatic factors. Our presented concepts of the "therapeutic model" based on pathophysiological investigations in multiple sclerosis show the tendency towards a "marked symptomatic therapy", which does not however, influence the basis of the disease processes, but rather represents an extremely helpful suppression of symptoms for the patients concerned.

Body Temperature↗